Skip to contentC
Collegium Pharmaceutical, Inc
C
COLLCollegium Pharmaceutical, Inc Q3 2020 · 10-Q
Revenue$79.18M$79.18M+8.5% vs Q3 2019 Net Income$11.29M$11.29MN/M vs Q3 2019 EPS Diluted$0.32$0.32N/M vs Q3 2019 Gross Profit$48,193,000+84.0% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Collegium Pharmaceutical, Inc · CIK 1267565 · Engraved from SEC EDGAR
Operating Cash Flowderived$34,180,000+463.2% Free Cash Flowderived$31,777,000+573.5% Margins · derivedGross margin60.9%+25.0 pt vs Q3 2019
Operating margin24.8%+33.5 pt vs Q3 2019
Net margin14.3%+22.6 pt vs Q3 2019
ended Sep 30, 2020 · filed Nov 5, 2020 · 36 d after period end